Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. Skyrizi is approved by the Food and Drug Administration (FDA ...

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...